Aldosterone

Aldosterone Full Name

Aldosterone

Aldosterone Introduction

Aldosterone is a mineralocorticoid hormone that plays a central role in maintaining electrolyte balance, blood pressure, and extracellular fluid volume, making it a critical biological target in both endocrine research and cardiovascular medicine. It is synthesized exclusively in the zona glomerulosa of the adrenal cortex, with the final and rate-limiting steps catalyzed by aldosterone synthase, encoded by the CYP11B2 gene. For researchers and clinicians, dysregulation of aldosterone signaling represents a persistent challenge: both excessive and deficient aldosterone production can lead to severe, sometimes life-threatening clinical consequences. Recent genetic studies have highlighted that even subtle alterations in CYP11B2 can profoundly disrupt aldosterone biosynthesis, underscoring why this pathway remains a high-value target for mechanistic studies, diagnostic development, and drug discovery.

Functionally, aldosterone acts primarily on the kidney, where it regulates sodium reabsorption and potassium excretion through activation of the mineralocorticoid receptor, thereby directly influencing blood pressure and serum potassium levels. Loss-of-function mutations in CYP11B2 impair the enzymatic conversion of corticosterone to aldosterone, resulting in aldosterone synthase deficiency characterized by hypoaldosteronism, hyperkalemia, dehydration, and failure to thrive, particularly in neonates and children. Recent family-based genetic analyses have revealed that different CYP11B2 variants can lead to variable degrees of enzyme dysfunction and highly heterogeneous clinical phenotypes, even among closely related individuals. These findings address a key pain point in clinical endocrinology: unexplained electrolyte abnormalities and hypotension that are difficult to diagnose without precise molecular insight into aldosterone biosynthesis.

From a disease and therapeutic perspective, aldosterone and CYP11B2 are equally important in conditions of hormone excess, such as primary hyperaldosteronism, a common but underdiagnosed cause of secondary hypertension. Beyond classical mineralocorticoid receptor antagonists, growing attention has shifted toward directly targeting aldosterone synthesis itself. Experimental studies have demonstrated that selective CYP11B2 inhibitors, including naturally derived small molecules, can suppress aldosterone production without broadly inhibiting cortisol synthesis, offering a more precise treatment strategy. In parallel, advances in immunohistochemistry using highly specific monoclonal antibodies against CYP11B2 now allow accurate localization of aldosterone-producing cells in adrenal tissue, improving pathological diagnosis and surgical decision-making. Together, these genetic, pharmacological, and diagnostic advances position aldosterone and CYP11B2 at the intersection of precision medicine, translational research, and unmet clinical need in hypertension and electrolyte disorders.

Alternate Names for Aldosterone

Aldosterone

• 1.Garrelfs MR, et al.; Identification of a Novel CYP11B2 Variant in a Family with Varying Degrees of Aldosterone Synthase Deficiency. J Clin Res Pediatr Endocrinol. 2024, 16(1):95-101.
  2.Liu W, et al.; Atractylenolide-I covalently binds to CYP11B2, selectively inhibits aldosterone synthesis, and improves hyperaldosteronism. Acta Pharm Sin B. 2022, 12(1):135-148.